Amedart

Amedart (LLC) develops and manufactures products from the list of vital and essential drugs (VEDs) and the Essential Medicines Supply Program (VEDs).

Aktivs

As of April 2022, the company has its own R&D center equipped with a full range of technological and analytical equipment. Pharmaceutical plant for the production of solid and liquid dosage forms is located in. SEZ "Technopolice" Moscow "

History

2023: Third highest number of clinical drug trials

At the end of 2023, 761 clinical trials of drugs were approved in Russia. Domestic pharmaceutical companies are replacing foreign drugs in terms of the number of studies carried out, and European and American organizations are replaced by manufacturers from the SCO and EAEU countries. This is stated in a study by the analytical firm Sciencefiles, the results of which were published in early February 2024.

The report says that in 2023, among domestic companies that received the most approvals in clinical drug trials, the leader changed. If in 2022 the first position was taken by Promomed with 51 projects, then in 2023 the Update company with 45 studies broke out to the top of the rating. In second place, as in 2022, was Pharmsintez - 39 projects, in third - Amedart with 34 studies. Read more here.

2022

Launch of drugs for the treatment of HIV and cancer

The company "Amedart" in the special economic zone "Technopolice Moscow" has launched an import-substituting production of drugs, including for the treatment of HIV infection and oncological diseases. To create this production, the Industrial Development Fund provided the company with a preferential loan under the Development Projects program in the amount of 100 million rubles, which was announced on April 19, 2022.

Current equipment will allow the company to produce drugs for the treatment of HIV with a production volume of up to 10 million packages per year and anticancer agents with a volume of up to 1 million packages per year.

Also, the plant began to produce immunosuppressants and drugs for the treatment of renal failure, it is planned to launch the production of insulins. In total, the company's portfolio for April 2022 has more than 60 products, all are included in the list of vital and essential drugs (vital and essential medicines). Production capacities will allow the production of up to 15 million packages per year of the entire range of the company's medicines.

Anti-HIV drugs are delivered to all regions of Russia as part of public procurement by the Ministry of Health of the Russian Federation and are issued free of charge on the basis of a federal program for patients in need of therapy.

The project is aimed at import substitution and an increase in the share of domestic drugs. One of the main advantages of Amedart products is a lower price with comparable quality to foreign counterparts.

Over the past 5 years, we have managed to assemble a team of first-class specialists, create a platform with high-tech equipment, develop and start producing drugs to save the lives of people who have faced serious diseases. More than 1.5 billion rubles have been invested in the creation of this production, "said Andrey Kolokoltsov, general director of Amedart LLC.

Cooperation with Tashir Medica to develop and manufacture drugs for the hospital sector

The memorandum of strategic cooperation in the field of pharmaceuticals and biotechnology was concluded by the resident of the SEZ "Technopolice Moscow" company "AMEDART" and the Group of Companies "Tashir MEDICA." The companies plan to produce antiretroviral, antitumor, antidiabetic, prescription and over-the-counter drugs for the hospital sector. This was announced by "Technopolice Moscow" on March 17, 2022.

Over the next ten years, the companies intend to develop strategic cooperation in the development, production and commercialization of drugs with international export potential, both in the territory and RUSSIAN FEDERATION EEU in other world markets. This will provide Russians high-quality drugs, as well as strengthen positions countries in the pharmaceutical market, - said the director of the special economic zone following the Gennady Degtev signing ceremony.

The document was signed by Andrey Kolokoltsov, General Director of AMEDART LLC, and Arsen Galstyan, Managing Partner of Tashir MEDICA Group of Companies.

The partnership between the companies involves the development of a common strategy for creating innovations in the pharmaceutical and biotechnology markets and joint scientific research. In addition, the companies intend to work closely in a number of areas in the field of digitalization of healthcare, for example, to create a new digital ecosystem that contributes to the acceleration of the scientific, technological and social-oriented development of the pharmaceutical industry.

AMEDART is aimed at providing the health care system with Russian medicines that are vital, as well as opening patients' access to modern therapy at affordable prices, said Andrey Kolokoltsov, CEO of the company.

Already in 2022, the production of 20 drugs will begin, including insulins, anticoagulants, anticancer agents. Cooperation with Tashir MEDICA will expand our existing capabilities, strengthen the scientific and production direction, - said the head of AMEDART.

According to Arsen Galstyan, managing partner of Tashir MEDICA Group of Companies, realities have faced new challenges and led to the need to organize autonomous intra-country cycles in many areas, primarily in strategically important and ensuring national security, life and health of citizens.

With partners from AMEDART, we will develop innovative products, approaches and standards in the pharmaceutical industry based on the latest achievements of science and technology, as well as digital solutions. We also plan to integrate this direction into the ecosystem of medical services on the principles of "beyond the pill," providing the most complete, integrative and personalized approach to the patient, "said Arsen Galstyan.

EAEU Good Manufacturing Practice Compliance Certificate

In January 2022, Amedart received Eurasian Economic Union EEU a GMP (Good Manufacturing Practice) certificate, which confirms the high quality standards of its products.

2020: Construction of a plant for the production of drugs for cancer and HIV in Moscow

On August 21, 2020, the Industrial Development Fund (FRP) announced that its expert council approved 6 loans for the implementation of projects in Moscow, Sverdlovsk and Vladimir regions, as well as in the Khabarovsk Territory. The amount of loans from the FRP will exceed 353.3 million rubles, and the total budget for the implementation of projects - 1.1 billion rubles.

The Moscow enterprise "Amedart" approved a loan for 100 million rubles under the flagship program of the FRP "Development Projects." The company organizes import-substituting production of anticancer drugs and agents for the treatment of HIV infection. The company's products are expected to replace about 5% of imports of similar drugs.

A plant for the production of drugs for cancer and HIV will appear in Moscow

In total, within the framework of the Amedart project on the territory of the Moscow Technopolice SEZ, it will create a high-tech pharmaceutical production of 48 drugs, including drugs for the therapy of retroviral infection, anticoagulants, insulins, drugs for the treatment of renal failure and anticancer drugs. All of them by August 21, 2020 are included in the list of vital drugs (VED) and have imported analogues.

The company notes that the main advantage of its products will be a lower price with similar quality. The developed drugs will be produced without the use of previously patented useful inventions, which will allow Amedart to sell medicines immediately after receiving registration certificates and entering medicines into the state register of maximum selling prices. The company has registered the drug "Gefitinib," used in non-small cell lung cancer.

In 2019, the Russian Ministry of Health spent about 23.6 billion rubles on the purchase of HIV drugs, and 29.3 billion rubles are planned for 2020 by the draft budget.^[1]

2019

Resident of the SEZ "Technopolice' Moscow '"

The Amedart company became a resident of the Moscow Technopolice SEZ in 2019.

Rename to Amedart

In 2019, the Inmedtrade enterprise was renamed Amedart LLC.

2009: Inmedtrade Education

In 2009, an enterprise called "Inmedtrade" was formed.

Notes